Michael Lin Baum

Michael L. Baum is the senior managing partner of Wisner Baum. He has successfully led the firm through thousands of wrongful death and personal injury cases stemming from major pharmaceutical drug catastrophes and commercial transportation mass disasters.

He began his career more than 30 years ago, primarily handling airline accidents and other commercial transportation disasters as well as some pharmaceutical product liability litigation. While he oversees all aspects of managing the firm, Michael currently heads the firm’s pharmaceutical litigation department and focuses on drug product liability mass tort and class action litigation as well as whistleblower qui-tam actions.

Under Michael’s leadership, Baum Hedlund has developed a reputation as a law firm that can be counted upon to go above and beyond what is needed to get the job done; a firm that has successfully litigated personal injury, wrongful death and consumer fraud cases against major pharmaceutical companies such as Alpha Therapeutic, Armour Pharmaceutical Co., Baxter Health Care Corp, Bayer Corp., Cutter Biologicals, Eli Lilly, GlaxoSmithKline, and Pfizer.

In addition, his firm is known for successfully resolving major transportation disaster cases against companies such as Airbus, Alaska Airlines, American Airlines, Amtrak, Bell Helicopter Co., Beechcraft, Boeing, Cessna, China Eastern Airlines, Continental Airlines, Delta Airlines, EgyptAir, Ford Motor Co., McDonnell Douglas, Piper, Robinson Helicopter Co., Sikorsky, SwissAir, TACA Airlines, TWA, United Airlines, and US Airways, among many others.

Medical officials from foreign governments in countries such as Ireland, Japan, Russia and Taiwan have sought Michael’s advice and assistance with their countries’ public policies concerning consumer drug safety. They’ve done so after becoming aware of Michael’s impressive understanding of biomedical research, clinical trials, statistics, the pharmaceutical industry and marketing, as well as his firm’s successful and effective discovery procedures and extensive work with experts on complicated scientific issues related to Baum Hedlund’s pharmaceutical litigation.